Wall Street analyst estimates for Azenta, Inc. (AZTA): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Azenta, Inc. is a global leader specializing in advanced solutions for the discovery, handling, and preservation of life science samples. The company's operations span across North America, Europe, Asia Pacific (including China), and other international markets. Its business is structured into two main reportable segments: Life Sciences Products and Life Sciences Services.
Analyst Consensus
| Strong Buy | 0 |
| Buy | 7 |
| Hold | 5 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 12 |
| Avg rating (1-5) | 0.58 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-20 | $0.09 | ||
| 2026-08-04 | $0.16 | $0.11 | +40.6% |
| 2026-05-06 | $-0.04 | $0.10 | -140.0% |
| 2026-02-04 | $0.09 | $0.11 | -18.2% |
| 2025-11-21 | $0.21 | $0.19 | +10.8% |
| 2025-08-05 | $0.19 | $0.13 | +46.2% |
| 2025-05-07 | $0.05 | $0.09 | -44.4% |
| 2025-02-05 | $0.08 | $0.05 | +60.0% |
Valuation Ratios
| Price / Book | 1.16 |
| EV / EBITDA | -14.87 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $560.3M | $527.5M | $631.6M | $780.8M | $388.5M | $513.7M | $555.5M | $665.1M | $573.4M | $593.8M |
| Cost of Revenue | $373.0M | $341.8M | $404.8M | $488.8M | $243.7M | $299.2M | $324.9M | $431.8M | $318.8M | $323.5M |
| Gross Profit | $187.3M | $185.7M | $226.7M | $292.0M | $144.9M | $214.5M | $230.6M | $233.3M | $254.6M | $270.3M |
| Research & Development | $51.5M | $39.9M | $46.9M | $56.4M | $16.1M | $22.4M | $27.5M | $34.0M | $31.5M | $30.4M |
| Selling, General & Admin | $116.3M | $127.6M | $145.4M | $180.5M | $156.3M | $188.5M | $227.1M | $281.5M | $253.1M | $251.2M |
| Operating Expenses | $167.8M | $167.5M | $192.3M | $236.9M | $172.4M | $210.9M | $254.6M | $315.5M | $284.6M | $281.5M |
| Operating Income | $19.5M | $18.2M | $34.4M | $55.1M | -$27.5M | $3.6M | -$24.0M | -$82.2M | -$30.0M | -$11.3M |
| EBITDA | $32.2M | $42.1M | $66.7M | $86.1M | $28.1M | $9.9M | $48.4M | $55.2M | $71.6M | $54.1M |
| Interest Expense | $157,000 | $408,000 | $9.5M | $22.2M | $2.9M | $2.0M | $4.6M | 0 | 0 | 0 |
| Pre-tax Income | $6.3M | $14.1M | $20.5M | $9.4M | -$40.3M | -$49.0M | -$9.9M | -$30.4M | -$19.1M | -$7.1M |
| Income Tax | $75.8M | $3.4M | -$47.3M | -$111,000 | -$13.9M | -$20.1M | $1.4M | -$17.6M | $5.2M | -$31.6M |
| Net Income | -$69.5M | $62.6M | $116.6M | $28.8M | $64.9M | $110.7M | -$429.0M | -$14.3M | -$164.9M | -$55.8M |
| EPS | $-1.02 | $0.90 | $1.65 | $0.14 | $0.88 | $1.49 | $-0.15 | $-0.22 | $-3.09 | $-1.22 |
| EPS (Diluted) | $-1.01 | $0.89 | $1.64 | $0.14 | $0.88 | $1.49 | $-0.15 | $-0.22 | $-3.09 | $-1.22 |
| Shares Outstanding (Diluted) | $68.5M | $70.5M | $70.9M | $72.4M | $73.8M | $74.5M | $74.9M | $66.3M | $53.2M | $45.9M |
Price
| Price | $42.73 |
| Market Cap | $2.0B |
| Exchange | NASDAQ |
| Country | US |
Related companies: BLFS · ESTA · EVO · KMTS · NEOG · NVCR · SDGR
Explore sector: Healthcare · Medical - Instruments & Supplies
More sections of AZTA: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Investment Academy — learn to analyze stocks